Darrin M. Beaupre

5.2k total citations
49 papers, 1.4k citations indexed

About

Darrin M. Beaupre is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Darrin M. Beaupre has authored 49 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 19 papers in Genetics and 18 papers in Oncology. Recurrent topics in Darrin M. Beaupre's work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (19 papers) and Viral-associated cancers and disorders (7 papers). Darrin M. Beaupre is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (19 papers) and Viral-associated cancers and disorders (7 papers). Darrin M. Beaupre collaborates with scholars based in United States, United Kingdom and France. Darrin M. Beaupre's co-authors include Razelle Kurzrock, Mathias G. Lichtenheld, Robert Buzzeo, Sven de Vos, Hongjie Deng, Peter Martin, Ian M. Leitch, Kelly S. Oliner, Robert Chen and Christopher J. Sweeney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Darrin M. Beaupre

48 papers receiving 1.4k citations

Peers

Countries citing papers authored by Darrin M. Beaupre

Since Specialization

Citations

This map shows the geographic impact of Darrin M. Beaupre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrin M. Beaupre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrin M. Beaupre more than expected).

Fields of papers citing papers by Darrin M. Beaupre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrin M. Beaupre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrin M. Beaupre. The network helps show where Darrin M. Beaupre may publish in the future.

Co-authorship network of co-authors of Darrin M. Beaupre

This figure shows the co-authorship network connecting the top 25 collaborators of Darrin M. Beaupre. A scholar is included among the top collaborators of Darrin M. Beaupre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darrin M. Beaupre. Darrin M. Beaupre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma 2024 ·Annals of Oncology ·Marcus O. Butler, Ryan Weight, Rizwan Haq, (unknown), (unknown), Bartosz Chmielowski, (unknown), Matteo S. Carlino, Meredith McKean, (unknown), Sriram Chandrasekaran, Seema A. Khan, (unknown), Jose Lutzky, Mark Shackleton, (unknown), Darrin M. Beaupre, George W. Cole, Hina Patel, (unknown)	2
2	A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma. 2024 ·Journal of Clinical Oncology ·Anthony M. Joshua, Roderick O’Day, William Glasson, David Sia, (unknown), Malaka Ameratunga, Rasha Cosman, Svetlana Cherepanoff, (unknown), Darrin M. Beaupre, (unknown), Li‐Anne Lim, John D. McKenzie, Daniel J. McKay, Mark Shackleton, Adrian T. Fung, Timothy Isaacs, (unknown), Christine Brooks, (unknown)	4
3	501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC) 2024 ·European Journal of Cancer ·(unknown), Melissa L. Johnson, Chun‐Gon Kim, A. W. Tolcher, (unknown), Charlene Mantia, (unknown), (unknown), Luis Paz-Ares Rodríguez, Thibault De La Motte Rouge, (unknown), (unknown), Long Kwei, (unknown), (unknown), (unknown), Mark White, Darrin M. Beaupre, (unknown)	1
4	1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM) 2023 ·Annals of Oncology ·Meredith McKean, Bartosz Chmielowski, Marcus O. Butler, (unknown), Jordi Rodón, Matteo S. Carlino, (unknown), Trisha M. Wise‐Draper, Shaheer Khan, April K.S. Salama, Justin C. Moser, James A. Reeves, Keith D. Wilner, Mathew S. Maurer, (unknown), Brent Mitchell, Darrin M. Beaupre, Marlana Orloff	7
5	Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development 2022 ·Frontiers in Oncology ·Timothy A. Yap, Ira Jacobs, (unknown), Lauren J. Lee, Darrin M. Beaupre, Laurent Azoulay	27
6	451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors 2022 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kerry Schaffer, (unknown), (unknown), (unknown), Darrin M. Beaupre, (unknown)	5
7	Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations 2021 ·Pediatric Drugs ·Elly Barry, (unknown), Scott L. Weinrich, Darrin M. Beaupre, Eileen Blasi, (unknown), Ira Jacobs	11
8	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma* 2021 ·Leukemia & lymphoma ·Wyndham H. Wilson, Tycel Phillips, Leslie Popplewell, Sven de Vos, Saurabh Chhabra, Amy Kimball, Darrin M. Beaupre, Da Wei Huang, George W. Wright, Kevin Kwei, Jerry Ping, Jutta K. Neuenburg, Louis M. Staudt	3
9	The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma 2020 ·British Journal of Haematology ·Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul Mena, R. Eric Davis, Sattva S. Neelapu, Karl Eckert, Jerry Ping, (unknown), Darrin M. Beaupre, Jutta K. Neuenburg, M. Lia Palomba	20
10	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma 2017 ·Molecular Cancer Therapeutics ·Hsu-Ping Kuo, Scott A. Ezell, Karl J. Schweighofer, Leo W.K. Cheung, (unknown), Mutiah Apatira, Mint Sirisawad, Karl Eckert, (unknown), Chun‐Te Chen, Darrin M. Beaupre, Matthias Versele, Betty Chang	45
11	A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE). 2017 ·Journal of Clinical Oncology ·Nathan Fowler, Ian W. Flinn, Simon Rule, Robert W. Chen, Long Kwei, Darrin M. Beaupre, Alvina D. Chu, Leo I. Gordon	1
12	Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies 2016 ·Haematologica ·Simon Rule, Martin Dreyling, Gregory P. Hess, Rebecca Auer, Brad S. Kahl, (unknown), (unknown), Fong Clow, Judith D. Goldberg, Darrin M. Beaupre, Jessica Vermeulen, Mark Wildgust, (unknown)	2
13	Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer A. Rizvi, Lisa Malburg, Vicki L. Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi‐Yuan Wu, Agnes Ang, Abdel‐Baset Halim, Robert A. Beckman, Darrin M. Beaupre, Jordan Berlin	74
14	A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·(unknown), Vicki L. Keedy, Pasi A. Jänne, Lorrin Yee, Naiyer A. Rizvi, (unknown), Catherine Copigneaux, Thore Hettmann, Darrin M. Beaupre, P. LoRusso	7
15	Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore	133
16	A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Peter J. Rosen, Christopher J. Sweeney, (unknown), Darrin M. Beaupre, Hongjie Deng, Ian M. Leitch, (unknown), Min Zhu, Kelly S. Oliner, Abraham Anderson, Lorrin Yee	60
17	Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results 2008 ·Cancer Research ·Angela Coxon, Karen Rex, Jan Sun, Jodi Moriguchi, (unknown), Mark Ma, Abraham Anderson, Yun Lan, Michael A. Gordon, Lia Gore, Christopher Sweeney, Lucy Yan, Darrin M. Beaupre, Kelly S. Oliner, Teresa L. Burgess	2
18	Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells 2005 ·Blood ·Kuichun Zhu, (unknown), Darrin M. Beaupre, (unknown), Carlos Muro‐Cacho, Craig A. Beam, Andrew D. Hamilton, Mathias G. Lichtenheld, William G. Kerr, William S. Dalton, Melissa Alsina, Saı̈d M. Sebti	38
19	Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells 2003 ·Leukemia & lymphoma ·Darrin M. Beaupre, (unknown), Nizar J. Bahlis, Lawrence Boise, Mathias G. Lichtenheld	15
20	RAS Inhibitors in Hematologic Cancers: Biologic Considerations and Clinical Applications 1999 ·Investigational New Drugs ·Darrin M. Beaupre, Razelle Kurzrock	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact